OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
April 01, 2009
Columns and Departments
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
Follow a risk-based approach to maintain a state of control.
Biodefense start-up companies have an abundance of options when seeking funding.
The FDA is poised to gain more authority and resources to ensure product quality.
"A systematic approach taken by a company involved making an assessment of internal capabilities, strengths, and needs before the selection process."
With all of the new expressions systems being developed, companies must decide what improved production and yield are really worth.
Can increase in ionic strength result in higher viscosity?
The 45 comments submitted raised concerns about legacy products and ongoing process monitoring.
The biopharmaceutical industry must continuously evolve to keep up with changing trends.
Cost modeling provides valuable insights to support strategic decision-making when implementing disposable technologies.